Statistics

Total Visits

Views
A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease37

Select a period of time:

Number of views in the range

Views
A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease23

Views

Views
October 20240
November 20241
December 20240
January 20251
February 20254
March 202517
April 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore17
United States6
 

Top cities views

Views
New York1
Pasadena1
Seattle1